Profil
Robert Shoemaker is currently the Senior Vice President-Research at Erasca, Inc. He previously worked as the Bioinformatics Director at Ignyta Operating, Inc. and as the Director-Bioinformatics Department at Ignyta, Inc. He also worked as a Scientist at Illumina, Inc. from 2011 to 2012.
Dr. Shoemaker obtained his undergraduate, graduate, and doctorate degrees from the University of California San Diego.
Postes actifs de Robert Shoemaker
| Sociétés | Poste | Début |
|---|---|---|
| ERASCA, INC. | Directeur Technique/Scientifique/R&D | 18/01/2022 |
Anciens postes connus de Robert Shoemaker
| Sociétés | Poste | Fin |
|---|---|---|
| ILLUMINA, INC. | Corporate Officer/Principal | 01/01/2012 |
| IGNYTA INC | Corporate Officer/Principal | - |
Ignyta Operating, Inc.
Ignyta Operating, Inc. Pharmaceuticals: MajorHealth Technology Develops molecular diagnostics for cancer and immunology | Corporate Officer/Principal | - |
Formation de Robert Shoemaker
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 5 |
|---|---|
Illumina, Inc.
Illumina, Inc. Medical SpecialtiesHealth Technology Operates as a biotechnology company that develops laboratory instruments | Health Technology |
Ignyta Operating, Inc.
Ignyta Operating, Inc. Pharmaceuticals: MajorHealth Technology Develops molecular diagnostics for cancer and immunology | Health Technology |
University of California San Diego
University of California San Diego Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Ignyta, Inc.
Ignyta, Inc. BiotechnologyHealth Technology Operates as a medicine biotechnology company which provides new drugs services for cancer patients | Health Technology |
Erasca, Inc.
Erasca, Inc. Pharmaceuticals: MajorHealth Technology Develops, discovers and commercializes therapies for RAS/MAPK pathway-driven cancers | Health Technology |
















